Overview

A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation

Status:
Completed

Trial end date:
1999-08-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the safety and effectiveness of oral risperidone (an antipsychotic medication) in the treatment of conduct disorder and other disruptive behavior disorders in children ages 5 to 12 with mild, moderate, or borderline mental retardation.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Pharmaceutica N.V., Belgium

Treatments:

Risperidone